Publications

Detailed Information

Mucinous Gastric Carcinomas Clinicopathologic and Molecular Analyses

DC Field Value Language
dc.contributor.authorChoi, Jong Sun-
dc.contributor.authorKim, Min A.-
dc.contributor.authorLee, Hee Eun-
dc.contributor.authorLee, Hye Seung-
dc.contributor.authorKim, Woo Ho-
dc.date.accessioned2012-05-31T00:26:49Z-
dc.date.available2012-05-31T00:26:49Z-
dc.date.issued2009-08-01-
dc.identifier.citationCANCER; Vol.115 15; 3581-90ko_KR
dc.identifier.issn0008-543X-
dc.identifier.urihttps://hdl.handle.net/10371/76634-
dc.description.abstractBACKGROUND: Mucinous gastric carcinoma (MGC) is characterized by substantial mucous lakes within tumors and comprises 3% of gastric carcinomas at the authors` institute. METHODS: The authors analyzed the clinicopathologic characteristics, mucin gene expression profiles, microsatellite instability (MSI), and status of the human epidermal growth factor receptor 2 (HER-2) and epidermal growth factor receptor (EGFR) genes in 133 MGCs and compared them with the same variables in nonmucinous gastric carcinomas (NMGCs). In addition, the prognostic implications of clinicopathologic parameters were evaluated. RESULTS: Patients who had MGC had deeper invasion (P=.003), more frequent lymph node metastasis (P<.001), more advanced pathologic stage (P<.001), more frequent lymphatic invasion (P<.001), and lower disease-specific survival rates (P<.0001) than patients who had NMGC. However, a mucinous histology per se was not identified as an independent prognostic factor. Negative mucin 1, cell surface associated (MUC1) status (P<.001); positive mucin 2, oligomeric mucus/gel-forming (MUC2) status (P<.001); negative mucin SAC, oligomeric mucus/gel-forming (MUC5AC) status (P=.036); and negative mucin 6, oligomeric mucus/gel-forming (MUC6) status (P<.001) were more frequent in MGCs. The frequency of MSI in MGC was not significantly different from that in NMGC. MGCs had a significantly lower incidence of HER-2 protein overexpression (P=.046), HER-2 gene amplification (P=.009), and EGFR protein overexpression (P=.017) than NMGCs; and multivariate analysis identified EGFR overexpression as a factor associated with a poor prognosis (P=.047). Patients with MGC who had a predominance of signet ring cells in mucin pools had poorer disease-specific survival than patients who had MGC with predominant tubular differentiation (P=.017). CONCLUSIONS: The clinicopathologic and molecular characteristics of MGCs differed from those of NMGCs. Furthermore, the results indicated that EGFR overexpression and histologic subtyping by predominant tumor cell type in mucin pools may be helpful for predicting clinical outcome in patients with MGC. Cancer 2009;115:3581-90. (C) 2009 American Cancer Society.ko_KR
dc.language.isoenko_KR
dc.publisherJOHN WILEY & SONS INCko_KR
dc.subjectstomach neoplasmsko_KR
dc.subjecterbB-2 geneko_KR
dc.subjecttissue array analysisko_KR
dc.subjectsurvival analysisko_KR
dc.subjectepidermal growth factor receptorko_KR
dc.subjectmicrosatellite instabilityko_KR
dc.subjectmucinous adenocarcinomako_KR
dc.subjectmucinsko_KR
dc.titleMucinous Gastric Carcinomas Clinicopathologic and Molecular Analysesko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor최종선-
dc.contributor.AlternativeAuthor김민아-
dc.contributor.AlternativeAuthor이희은-
dc.contributor.AlternativeAuthor이혜승-
dc.contributor.AlternativeAuthor김우호-
dc.identifier.doi10.1002/cncr.24422-
dc.citation.journaltitleCANCER-
dc.description.citedreferenceFalchetti M, 2008, HUM PATHOL, V39, P925, DOI 10.1016/j.humpath.2007.10.024-
dc.description.citedreferenceKim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x-
dc.description.citedreferenceHidaka S, 2008, HEPATO-GASTROENTEROL, V55, P791-
dc.description.citedreferencePEREZ RO, 2008, INT J COLORECTAL DIS, V23, P57-
dc.description.citedreferenceAdsay NV, 2006, AM J GASTROENTEROL, V101, P2330, DOI 10.1111/j.1572-0241.2006.00934.x-
dc.description.citedreferencePark SY, 2006, VIRCHOWS ARCH, V449, P40, DOI 10.1007/s00428-006-0212-7-
dc.description.citedreferenceKunisaki C, 2006, ANN SURG ONCOL, V13, P836, DOI 10.1245/ASO.2006.03.077-
dc.description.citedreferenceOgino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482-
dc.description.citedreferenceKimura M, 2004, VIRCHOWS ARCH, V445, P255, DOI 10.1007/s00428-004-1048-7-
dc.description.citedreferencePinto-de-Sousa J, 2004, VIRCHOWS ARCH, V444, P224, DOI 10.1007/s00428-003-0968-y-
dc.description.citedreferencePAPADOPOULOS VN, 2004, TECH COLOPROCTOL S1, V8, pS123-
dc.description.citedreferenceLuttges J, 2003, MODERN PATHOL, V16, P537, DOI 10.1097/01.MP.0000072748.65178.2F-
dc.description.citedreferenceLee HS, 2002, MODERN PATHOL, V15, P632-
dc.description.citedreferenceGurbuz Y, 2002, VIRCHOWS ARCH, V440, P505, DOI 10.1007/s00428-002-0620-2-
dc.description.citedreferenceWoo LS, 2002, DIGEST SURG, V19, P286-
dc.description.citedreferenceYasuda K, 2001, J SURG ONCOL, V76, P272-
dc.description.citedreferenceTajima Y, 2001, ONCOLOGY-BASEL, V61, P212-
dc.description.citedreferenceHAMILTON SR, 2001, WHO CLASSIFICATION T-
dc.description.citedreferenceKAWAMURA H, 2001, GASTRIC CANCER, V4, P83-
dc.description.citedreferenceKang GH, 1999, MODERN PATHOL, V12, P15-
dc.description.citedreferenceBoland CR, 1998, CANCER RES, V58, P5248-
dc.description.citedreferenceWu CY, 1998, CANCER, V83, P1312-
dc.description.citedreferenceWirtz HC, 1998, CLIN CANCER RES, V4, P1749-
dc.description.citedreferenceBaldus SE, 1998, INT J CANCER, V79, P133-
dc.description.citedreferenceHayden JD, 1997, EUR J CANCER, V33, P2342-
dc.description.tc3-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share